Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669318 | 1.00 | CTSK (0.49) | CTSKCTSSALDH1A1LMNAPKM | |
| SCHEMBL669317 | 1.00 | CTSK (0.49) | CTSKCTSSALDH1A1LMNAPKM | |
| SCHEMBL1643165 | 0.87 | CTSK (0.47) | CTSKCTSSALDH1A1LMNAPKM | |
| SCHEMBL19954205 | 0.87 | CTSK (0.47) | CTSKCTSSALDH1A1LMNAPKM | |
| SCHEMBL3337069 | 0.87 | CTSS (0.43) | CTSKCTSSALDH1A1LMNAPKM | |
| SCHEMBL391352 | 0.87 | PPARG (0.42) | CTSKCTSSALDH1A1LMNAPKM | |
| SCHEMBL1642073 | 0.87 | CTSK (0.47) | CTSKCTSSALDH1A1LMNAPKM | |
| SCHEMBL16805937 | 0.87 | HPGD (0.46) | CTSKCTSSALDH1A1LMNAPKM | |
| SCHEMBL21509860 | 0.86 | ALDH1A1 (0.46) | CTSKCTSSALDH1A1LMNAPKM | |
| SCHEMBL21509779 | 0.86 | CACNA1B (0.43) | CTSKCTSSALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220242831-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES | DR. REDDY'S LABORATORIES LIMITED (IN) | 2022-08-04 | — | — | US | claimed |
| US-20250084042-A1 | Elagolix Sodium Compositions and Processes | ABBVIE INC. | 2025-03-13 | — | — | US | disclosed |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-01-09 | — | — | US | disclosed |
| WO-2024010810-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-11858901-B2 | 3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix | MOEHS IBERICA, S.L. (ES) | 2024-01-02 | — | — | US | disclosed |
| CN-115856138-A | Method for separating and determining related substances in oxa-degril sodium by using HPLC (high performance liquid chromatography) | 安徽联创生物医药股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11542239-B2 | Elagolix sodium compositions and processes | ABBVIE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220411382-A1 | 3-((R)-2-(AMINO-2-PHENYLETHYL)-1-(2-FLUORO-6 TRIFLUOROMETHYL BENZYL)-5-IODO-6-METHYL-1H-PYRIMIDINE-2,4-DIONE OR A SALT THEREOF, PROCESS FOR ITS PREPARATION, AND ITS USE IN THE SYNTHESIS OF ELAGOLIX | MOEHS IBERICA S.L. (ES) | 2022-12-29 | — | — | US | disclosed |
| US-11498903-B2 | 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-10-13 | — | — | US | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192132-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001096303-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076971-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0365045-B1 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1993-12-01 | — | — | EP | disclosed |
| EP-0161801-B1 | PERHYDROTHIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANKYO COMPANY LIMITED (JP) | 1990-11-07 | — | — | EP | disclosed |
| EP-0365045-A1 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1990-04-25 | — | — | EP | disclosed |
| US-4699905-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1987-10-13 | — | — | US | disclosed |
| EP-0161801-A2 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411382-A1 | 3-((R)-2-(AMINO-2-PHENYLETHYL)-1-(2-FLUORO-6 TRIFLUOROMETHYL BENZYL)-5-IODO-6-METHYL-1H-PYRIMIDINE-2,4-DIONE OR A SALT THEREOF, PROCESS FOR ITS PREPARATION, AND ITS USE IN THE SYNTHESIS OF ELAGOLIX | JAK2, EML4, AZI2 | CTSK 4797/4885CTSS 4867/4885ALDH1A1 1234/4885 |
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | QDPR, SIRT5, PDXK | CTSK 1358/4885CTSS 1873/4885ALDH1A1 767/4885 |
| US-11542239-B2 | Elagolix sodium compositions and processes | ELOVL5, ELOC, ELOVL3 | CTSK 2635/4885CTSS 3505/4885ALDH1A1 1582/4885 |
| US-20250084042-A1 | Elagolix Sodium Compositions and Processes | ELOVL5, ELOC, ELOVL3 | CTSK 2635/4885CTSS 3505/4885ALDH1A1 1582/4885 |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CTSK 965/4885CTSS 2805/4885ALDH1A1 3081/4885 |
| US-11498903-B2 | 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases | APLNR, AP3B1, AP2B1 | CTSK 2246/4885CTSS 4522/4885ALDH1A1 558/4885 |
| US-20220242831-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES | PCSK9, XPO5, HAX1 | CTSK 2386/4885CTSS 3193/4885ALDH1A1 1721/4885 |
| US-11858901-B2 | 3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix | JAK2, EML4, AZI2 | CTSK 4797/4885CTSS 4867/4885ALDH1A1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.